Mind Medicine, Inc.’s Nasdaq Up-Listing

Wildeboer Dellelce LLP acted for MindMed in its Nasdaq up-listing

Mind Medicine (MindMed) Inc. has completed its up-listing to The Nasdaq Capital Market, where its subordinate voting shares will begin trading under the symbol “MNMD”. MindMed will retain its listing on the Neo Exchange Inc. under the symbol “MMED”. The Nasdaq listing is anticipated to increase MindMed’s visibility in the marketplace, improve liquidity, broaden and diversify MindMed’s shareholder base, and ultimately enhance long-term shareholder value. Upon the commencement of trading on Nasdaq, the market cap of Mindmed exceeded US $1.0 Billion.

MindMed is a leading psychedelic medicine biotech company. 

The Wildeboer Dellelce team included Perry Dellelce (Picture), Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities).

Involved fees earner: Rebecca Cochrane – Wildeboer Dellelce LLP; Perry Dellelce – Wildeboer Dellelce LLP; Peter Volk – Wildeboer Dellelce LLP;

Law Firms: Wildeboer Dellelce LLP;

Clients: Mind Medicine Inc;

Martina Bellini

Author: Martina Bellini